Stem Cell Therapy for Liver Failure
Author Information
Author(s): Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma, Edward A. Carter, François Berthiaume, Arno W. Tilles, Martin L. Yarmush
Primary Institution: Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School
Hypothesis
The paracrine function of mesenchymal stem cells (MSCs) may be of therapeutic value in acute organ failure.
Conclusion
MSC-derived molecules can protect against liver cell death and increase survival in a rat model of fulminant hepatic failure.
Supporting Evidence
- MSC-CM treatment significantly reduced liver injury biomarkers.
- 71% of rats treated with MSC-EB survived compared to 14% in control groups.
- Histological analysis showed reduced immune cell infiltration in MSC-CM treated rats.
Takeaway
Scientists found that special cells from bone marrow can help sick livers heal and save lives in rats.
Methodology
Rats were treated with MSC-derived conditioned medium or a bioreactor containing MSCs after inducing liver failure.
Limitations
The study was conducted in rats, and results may not directly translate to humans.
Participant Demographics
Sprague-Dawley rats were used in the study.
Statistical Information
P-Value
p<0.032
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website